The Body Cannot Dissolve Them: Scientists Prove That White Clots Are Degradation-Resistant Amyloid Structures | Greg Harrison

White Clots Removed from Bodies Still Trigger Protein Misfolding Three Months Later

https://flashlightsproductions.substack.com/p/the-body-cannot-dissolve-them-scientists?utm_source=youtube

"This is truly groundbreaking" —Greg Harrison

"We had to find a lab, we had to fund it ourselves. It's all out of our own pocket…

"We have forensic grade proof that the material is amyloid like… The proteins have not merely lost their native fold, they have adopted a new thermodynamically stable architecture.

"Data is data and facts are facts. And these are facts. So all we can do is present the facts…

"We challenge people. If you disagree with it, you go and rerun the work, you go and get the Raman analysis and prove us wrong."

Greg Harrison is an organic chemist based in Sydney, Australia. For the past two years, he has been working with a small international team of scientists analyzing unusual white, rubbery, fibrous clots found inside the blood vessels of deceased people — and also in living people.

These white clots began appearing in corpses in late spring 2021, shortly after the mRNA vaccine rollout began, and they are still being found today. Embalmers were the first to notice them; vascular surgeons have since found them in living patients as well.

Greg's team now believes these white clots are amyloid or amyloid-like which means that they consist of misfolded proteins that have locked into a rigid, crystalline structure.

Amyloidosis is a group of diseases that are caused by misfolded proteins building up in organs, including the brain. Alzheimer's is one of them, Lewy body diseases another.

Greg told me that there are 36 known different types of amyloidosis in total and that the white clots are a completely new type of amyloidosis: a blood-borne systemic amyloidosis, never seen before.

Traditional amyloidosis develops slowly over decades. But this white clot amyloidosis develops much faster, namely within months. These white structures were seen by embalmers in corpses for the first time in spring of 2021, just months after the mRNA Covid mass injection campaign had begun.

CHAPTERS

00:05 Opening And Recap Of The White Clot Mystery

00:49 Greg Harrison's Claim: White Clots Are Amyloid‑Like

03:04 What Is Amyloidosis? From Rare Brain Disease To Blood‑Borne Systemic Form

05:50 Known Amyloid Diseases And Why Misfolding Matters

06:17 Early Analytical Work: Phosphorylation, Sulfation And Misfolded Fibrinogen

10:30 Thioflavin T Fluorescence And Elemental Signals In Embalmer Clots

14:51 Kevin McCairn's Findings: Misfolded Amyloidogenic Fibrin And Systemic Risks

19:05 Infective Peptide Concept: White Clots Seeding Misfolding In Fresh Plasma

20:19 Microscopy Of "Calamari" Clots And RT‑QuIC Seeding Experiments

25:18 Amyloid‑Prion‑Like Behavior And Caution About True Prion Claims

27:00 Why Raman Spectroscopy Is Definitive For Detecting Amyloid Structure

28:37 Raman Fingerprints Of Clot Samples Showing Progression Toward Beta Sheets

31:18 Reference Spectra: Healthy Plasma, Fibrinogen And Spike‑Protein Bands

34:16 European Raman Lab Work And Peer‑Reviewed Paper Preparation

35:09 "Amyloidogenic Scaffolds": Converging Raman And ThT Evidence

37:30 Novel Intravascular Scaffolds And Why They Differ From Standard Clots

38:34 Structural Reorganization: From Flexible Proteins To Rigid Crystalline Lattice

41:02 Lab Conclusion: Self‑Assembling Amyloid Scaffold, Not Reversible Clotting

42:36 Data, University Backing, And Anticipated Pushback From Institutions

43:45 Explaining Aromatic Packing And Why These Scaffolds Resist Breakdown

44:39 Possible Dissolution: Stem‑Cell Approaches And Other Anti‑Amyloid Strategies

46:09 Microclots, Strokes And Links To Long COVID And Fibrin(oid) Deposits

47:22 Microclots In Vaccinated And Unvaccinated: Role Of Open Spike Conformation

49:34 Speed Of Clot Emergence After mRNA Rollout And Survey Data

50:06 Apheresis In Japan: Blood‑Filtering To Remove Amyloid Microclots

51:08 Follow‑Up Outcomes: Patients Remaining Clot‑Free For 6–8 Months

51:29 Self‑Amplifying RNA, Broader mRNA Platform Concerns And Phosphorylation

54:02 Lack Of Interest From Australian Public Health And Self‑Funded Research

55:28 Future Tests: Focused Raman On Spike Region And Phosphorus NMR

RESOURCES Raman spectroscopic Characterization of Anomalous Intravascular Fibrous Casts: Evidence for Stage-Dependent β-sheet Enriched Protein Maturation, International Journal of Innovative Research in Medical Science; Authors: Daniel Santiago, Greg Harrison, Miklos Veres, Mark File and Dennis Planner: https://ijirms.in/index.php/ijirms/article/view/2202

Australian Amyloidosis Network: https://aan.org.au/patients-and-carers/what-is-amyloidosis/

Douglas B. Kell and Etheresia Pretorius: Proteomic Evidence for Amyloidogenic Cross-Seeding in Fibrinaloid Microclots https://www.mdpi.com/1422-0067/25/19/10809